Skip to content
Clinical Trials – home

Institutul Regional De Oncologie Iasi

Verified siteinfo

Romania Strada G-Ral Berthelot 2-4, 700483 Iasi, Romania

  • 46 trials recruiting
  • Non-small cell lung cancer · Breast cancer · Non-small cell lung cancer metastatic
  • Adults and children

About Specializations

Institutul Regional De Oncologie Iasi in Iasi, Romania specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Non-small cell lung cancer metastatic, Colorectal cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

At Institutul Regional De Oncologie Iasi, clinical research is centered on oncology, with studies focused on major cancer types and the search for better ways to manage and understand malignant disease. The trials are designed to support improved treatment options and more effective care for patients.

  • Research on cancer care and treatment improvement
  • Studies exploring new approaches for oncology patients

With a team of 17 investigators, the site contributes to advancing cancer research in Iasi and supports the development of more effective therapies and patient care strategies.

Clinical Research

The clinical trial activity at this Romanian research center includes efforts aimed at improving diagnosis, treatment evaluation, and overall understanding of serious disease. These studies help generate evidence that can guide better clinical decisions and patient management.

  • Evaluation of treatment effectiveness in medical research
  • Studies supporting better diagnosis and disease monitoring

This work reflects the site’s role as an active clinical research location in Europe, contributing to evidence-based care through carefully designed studies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Strada G-Ral Berthelot 2-4700483 IasiRomania
Recruiting now
46 trials
Conditions studied
74
Partner status
Verified site

More sites in IasiRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

80 clinical trials

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.